IL185861A - Pharmaceuticals for the treatment of inflammatory bowel disease, cancer and pre-malignant conditions containing derivatives 13,14-dihydro-15-keto-16,16-dipluoro pge1 - Google Patents

Pharmaceuticals for the treatment of inflammatory bowel disease, cancer and pre-malignant conditions containing derivatives 13,14-dihydro-15-keto-16,16-dipluoro pge1

Info

Publication number
IL185861A
IL185861A IL185861A IL18586107A IL185861A IL 185861 A IL185861 A IL 185861A IL 185861 A IL185861 A IL 185861A IL 18586107 A IL18586107 A IL 18586107A IL 185861 A IL185861 A IL 185861A
Authority
IL
Israel
Prior art keywords
keto
difluoro
dihydro
cancer
pharmaceutical compositions
Prior art date
Application number
IL185861A
Other languages
English (en)
Hebrew (he)
Other versions
IL185861A0 (en
Original Assignee
Sucampo Ag
Univ North Carolina State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Ag, Univ North Carolina State filed Critical Sucampo Ag
Publication of IL185861A0 publication Critical patent/IL185861A0/en
Publication of IL185861A publication Critical patent/IL185861A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL185861A 2005-03-21 2007-09-10 Pharmaceuticals for the treatment of inflammatory bowel disease, cancer and pre-malignant conditions containing derivatives 13,14-dihydro-15-keto-16,16-dipluoro pge1 IL185861A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US66320005P 2005-03-21 2005-03-21
US67992005P 2005-05-11 2005-05-11
US72197605P 2005-09-30 2005-09-30
PCT/JP2006/306380 WO2006101244A2 (en) 2005-03-21 2006-03-22 Method and composition for treating mucosal disorders

Publications (2)

Publication Number Publication Date
IL185861A0 IL185861A0 (en) 2008-01-06
IL185861A true IL185861A (en) 2015-06-30

Family

ID=36754577

Family Applications (1)

Application Number Title Priority Date Filing Date
IL185861A IL185861A (en) 2005-03-21 2007-09-10 Pharmaceuticals for the treatment of inflammatory bowel disease, cancer and pre-malignant conditions containing derivatives 13,14-dihydro-15-keto-16,16-dipluoro pge1

Country Status (14)

Country Link
US (1) US20060281818A1 (enExample)
EP (3) EP1861169B1 (enExample)
JP (2) JP5219797B2 (enExample)
KR (2) KR101456298B1 (enExample)
CN (1) CN103948603A (enExample)
AU (1) AU2006225515B2 (enExample)
BR (1) BRPI0609672A2 (enExample)
CA (2) CA2601158C (enExample)
ES (1) ES2592283T3 (enExample)
IL (1) IL185861A (enExample)
MX (1) MX2007011645A (enExample)
NO (1) NO20075361L (enExample)
NZ (3) NZ562351A (enExample)
WO (1) WO2006101244A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004037268A1 (en) * 2002-10-23 2004-05-06 Sucampo Ag Prostaglandin compounds for the treatment of obesity
US20060281818A1 (en) * 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
EP2059247A1 (en) 2006-09-06 2009-05-20 Sucampo AG Method and composition for promoting gastrointestinal bicarbonate secretion
WO2009055769A1 (en) 2007-10-25 2009-04-30 Phytoceutica, Inc. Use of phy906 as treatment for inflammatory bowel disease and/or irritable bowel syndrome
US8871752B2 (en) * 2008-02-19 2014-10-28 Sucampo Ag Method for modulating stem cell growth
US8569279B2 (en) 2009-05-27 2013-10-29 Sucampo Ag Method for modulating claudin mediated functions
US20100305203A1 (en) * 2009-05-27 2010-12-02 Sucampo Ag Method for modulating claudin mediated functions
US9084815B2 (en) * 2009-09-16 2015-07-21 Sucampo Ag Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor
EP2699244A4 (en) * 2011-04-19 2014-10-22 Sucampo Ag METHOD FOR MODULATING CYTOKINACTIVITY
EP2701709A4 (en) * 2011-04-27 2014-10-15 Sucampo Ag METHOD FOR MODULATING ION TRANSPORTERS
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
US20150099802A1 (en) * 2013-10-03 2015-04-09 Sucampo Ag Selective tumor treatment
US20160120840A1 (en) * 2014-10-30 2016-05-05 Sucampo Ag Method and composition for treating nonerosive reflux disease
PL3292135T3 (pl) * 2015-05-06 2023-01-02 Wageningen Universiteit Zastosowanie polipeptydu do wpływania na sygnalizację odpornościową i/lub wpływania na funkcję bariery jelitowej i/lub modulowania stanu metabolicznego
WO2024217532A1 (zh) * 2023-04-20 2024-10-24 中南大学湘雅二医院 Carboprost在制备抗肿瘤药物中的应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2645710C2 (de) * 1976-10-09 1985-06-27 Merck Patent Gmbh, 6100 Darmstadt Phenoxy-amino-propanole, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitung
GB1581886A (en) * 1977-05-26 1980-12-31 May & Baker Ltd Prostanol derivatives
JPS58216155A (ja) * 1982-06-10 1983-12-15 Ono Pharmaceut Co Ltd 新規なプロスタグランジンｄ類似化合物
JPS591463A (ja) * 1982-06-28 1984-01-06 Ono Pharmaceut Co Ltd 新規なプロスタグランジンｄ類似化合物
FR2608924B1 (fr) * 1986-12-29 1990-07-20 Pasteur Institut Compositions therapeutiques contenant des derives soufres de prostaglandines, nouveaux derives soufres et leur procede de preparation
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5225439A (en) 1987-01-28 1993-07-06 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
CA1323364C (en) * 1987-01-28 1993-10-19 Ryuzo Ueno Prostaglandins e and anti ulcer agents containing same
US5428062A (en) * 1987-01-28 1995-06-27 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
US5317032A (en) 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
JP2579193B2 (ja) * 1988-07-19 1997-02-05 小野薬品工業株式会社 １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体
CA2030345C (en) * 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
CA2039420C (en) 1990-04-04 1996-12-10 Ryuji Ueno Treatment of cataract with 15-keto-prostaglandin compounds
CA2046069C (en) * 1990-07-10 2002-04-09 Ryuji Ueno Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
US5234858A (en) 1990-11-16 1993-08-10 Micron Technology, Inc. Stacked surrounding wall capacitor
KR940007277B1 (ko) 1992-02-14 1994-08-12 한국과학기술원 2차 전지 전극용 수소 저장 합금
US5376034A (en) 1992-05-27 1994-12-27 Brunswick Corporation Marine drive exhaust system
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
JP3183615B2 (ja) * 1994-06-03 2001-07-09 株式会社アールテック・ウエノ 肝・胆道系疾患処置剤
US6558708B1 (en) * 1995-05-17 2003-05-06 Cedars-Sinai Medical Center Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
EP0857718B1 (en) 1996-06-10 2002-08-14 Sucampo AG Endothelin antagonist
US5876034A (en) 1997-12-17 1999-03-02 Stafford; James R. Sporting fishing board game
US6492417B1 (en) * 1997-12-22 2002-12-10 Alcon Manufacturing, Ltd. 11-deoxy-16-fluoro-PGF2α analogs as FP receptor antagonists
US6610713B2 (en) * 2000-05-23 2003-08-26 North Shore - Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US6414016B1 (en) 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
US6919082B2 (en) * 2001-02-13 2005-07-19 Kirin Beer Kabushiki Kaisha Pharmacological composition containing yeast cell wall fraction
GB2375349A (en) * 2001-02-13 2002-11-13 Glaxo Group Ltd Chloride intracellular channel-related proteins
GB0111497D0 (en) * 2001-05-11 2001-07-04 Medical Res Council Therapeutic methods
MXPA04002006A (es) * 2001-08-31 2004-06-07 Sucampo Ag Analogos de prostagladina como abridor del canal de cloruro.
AR037524A1 (es) 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
US7732487B2 (en) 2001-11-19 2010-06-08 Sucampo Ag Method for treating a disease or condition responsive to opening of C1C-2 channel
MXPA05006981A (es) * 2002-12-27 2005-12-14 Sucampo Ag Derivados de prostaglandinas para el tratamiento de la molestia abdominal.
US7855226B2 (en) * 2003-02-11 2010-12-21 Allergan, Inc. Treatment of inflammatory bowel disease
US7169807B2 (en) * 2004-04-09 2007-01-30 Allergan, Inc. 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists
CA2585367A1 (en) * 2004-10-26 2006-05-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
US20060281818A1 (en) * 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders

Also Published As

Publication number Publication date
NO20075361L (no) 2007-12-20
CA2831416C (en) 2016-12-13
EP2384791A2 (en) 2011-11-09
IL185861A0 (en) 2008-01-06
EP2384791A3 (en) 2011-12-28
ES2592283T3 (es) 2016-11-29
JP2012180380A (ja) 2012-09-20
EP1861169B1 (en) 2016-05-11
KR20140072102A (ko) 2014-06-12
JP2008533195A (ja) 2008-08-21
CA2601158A1 (en) 2006-09-28
JP5777574B2 (ja) 2015-09-09
JP5219797B2 (ja) 2013-06-26
US20060281818A1 (en) 2006-12-14
WO2006101244A2 (en) 2006-09-28
CA2601158C (en) 2015-10-13
MX2007011645A (es) 2007-11-16
AU2006225515B2 (en) 2012-02-02
KR20080012266A (ko) 2008-02-11
KR101456298B1 (ko) 2014-11-03
EP2384790A2 (en) 2011-11-09
WO2006101244A3 (en) 2007-02-08
AU2006225515A8 (en) 2006-09-28
NZ597857A (en) 2013-08-30
EP2384790A3 (en) 2011-12-28
CA2831416A1 (en) 2006-09-28
AU2006225515A1 (en) 2006-09-28
NZ588878A (en) 2012-05-25
NZ562351A (en) 2010-12-24
BRPI0609672A2 (pt) 2010-04-20
EP2384791B1 (en) 2016-06-15
CN103948603A (zh) 2014-07-30
EP1861169A2 (en) 2007-12-05

Similar Documents

Publication Publication Date Title
IL185861A (en) Pharmaceuticals for the treatment of inflammatory bowel disease, cancer and pre-malignant conditions containing derivatives 13,14-dihydro-15-keto-16,16-dipluoro pge1
IL189008A (en) History of 1-Naphthalenyl-3-azabicyclo [0.1.3] hexane
IL184901A0 (en) 2,4-diamino-pyridopyrimidine derivatives and their use as mtor inhibitors
IL225207A (en) A derivative of multi-ring carbamoylpyridone, its pharmaceutical composition, its use and its preparation
IL193467A0 (en) Substituted indazole derivatives, their manufacture and use as pharmaceutical agents
LT1965816T (lt) Farmacinės kompozicijos ir metodai, skirti su oksalatu susijusių ligų gydymui arba prevencijai
IL173908A0 (en) Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
PT1611091E (pt) Cristais estáveis de natamicina em forma de agulha
PL1928882T3 (pl) (S)-N-Metylonaltrekson, sposoby jego syntezy i jego zastosowania farmaceutyczne
PL375874A1 (pl) Wodne kompozycje farmaceutyczne 2,6-diizopropylofenolu
IL187235A0 (en) 2,6 quinolinyl derivatives, processes for preparing them and their use as medicament
EP2034835A4 (en) NONTOXIC CANCER WITH A COMBINATION OF ASCORBATE, MAGNESIUM AND A NAPHTHOCHINONE
IL196136A (en) Its aminoindane or salt derivative, the pharmaceutical composition containing them and their uses
ZA200706672B (en) 2,4-Diamino-pyridopyrimidine derivatives and their use as mTOR inhibitors
IL190841A0 (en) Pharmaceutical compositions and diagnostic methods for inflammatory skin diseases, disorders or conditions
ZA200805419B (en) Compositions and methods for preventing or treating inflammatory bowel disease
IL186748A0 (en) 4 - phenyl - 5 - oxo 1, 4, 5, 6, 7, 8 - hexahydroquinoline derivatives for the treatment of infertility
PL394600A1 (pl) Związek winyloazacykloalkanowy, sposób jego wytwarzania i jego zastosowanie oraz kompozycja farmaceutyczna
TWI315305B (en) Piperidin-4-yl-amide derivatives,pharmaceutical compositions comprising the same,process for preparing the same and the use thereof
IL176836A (en) Converged phenoxy and phenylthione and intermediates, a process for their preparation, a pharmaceutical composition comprising them, a pair comprising them and their use
EP1583966A4 (en) METHODS AND COMPOSITIONS FOR TREATING CARDIOVASCULAR DISEASES USING GENES 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061, 17662, 1468, 12282, 6350, 9035, 1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123, 12788, 17729, 65552, 1261, 21476, 33770, 9380, 2569654, 33
IL170315A (en) Cycloalkyl-substituted alkanoic acid derivatives, pharmaceutical compositions and use thereof
SI2020410T1 (sl) Derivati pirido(2,3-d)pirimidina, njihova priprava, njihova terapevtska uporaba
PL374461A1 (pl) Sposób otrzymywania pochodnych 13,14-dihydro-PGF
SI1791872T1 (sl) Biotinilirani heksadekasaharidi, farmacevtski sestavki in njihova uporaba

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees